1. Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study
- Author
-
Robert R. Redfield, Nathan Clumeck, Daniel Zagury, Bruce L. Gilliam, Robert C. Gallo, Hélène Le Buanec, Arsène Burny, Bernard Bizzini, and Philippe Hermans
- Subjects
lcsh:Immunologic diseases. Allergy ,biology ,business.industry ,Toxoid ,Viremia ,Drug holiday ,Sciences bio-médicales et agricoles ,medicine.disease ,Placebo ,Virology ,complex mixtures ,Vaccination ,Infectious Diseases ,Immune system ,Apoptosis ,Immunology ,biology.protein ,Medicine ,Oral Presentation ,Antibody ,business ,lcsh:RC581-607 - Abstract
Anti-Tat therapeutic vaccination has been clinically investigated by different groups [1-4], given that 1) extracellular Tat protein induces T cell apoptosis and cellular immune suppression, 2) epidemiological data showed that LTNP exhibit high level of serum anti-Tat Ab, negatively correlated with p24 antigenemia, 3) in Tat immunized macaques, viremia decreased following SHIV challenge. Anti-Tat therapeutic vaccination using Tat Toxoid adjuvanted either with Seppic [1,2] or with alum or DcChol (Aventis Pasteur) proved to be safe. A prospective structured treatment interruption study (STI) monitored according to EU guidelines was conducted at Hospital St-Pierre, Brussels (Pr. N. Clumeck) on 31 vaccinees who received a DcChol adjuvanted Tat Toxoid (n = 12), a DcChol placebo (n = 8) or non adjuvanted Tat toxoid (n = 11). The 2 year study follow-up showed that vaccinees developing high titer of Abs neutralizing Tat bioactivity prolonged HAART-interruption., info:eu-repo/semantics/published, Oral presentation. From 2006 International Meeting of The Institute of Human VirologyBaltimore, USA. 17–21 November, 2006
- Published
- 2006